Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Clinical Research

Vol 9 No 2 (2024): December

Histological and Physiological Study of Hyaluronic Acid Filler (Neuramis) in Laboratory Rats
Studi Histologis dan Fisiologis Filler Asam Hyaluronic (Neuramis) pada Tikus Laboratorium



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.10382
Published
December 7, 2024

Abstract

Hyaluronic acid (HA) dermal fillers, derived from animal or non-animal sources, vary in physical and chemical properties, with numerous clinical trials assessing their effectiveness. This study examined the effects of Neuramis Volume Lidocaine on experimental animals over five durations (2, 4, 9, 10, and 13 weeks) via subcutaneous injections of 0.1 ml. Results showed a significant reduction in red blood cells, hemoglobin, and platelets after two weeks, which normalized by weeks 10 and 13. White blood cells and neutrophils significantly increased at two weeks but stabilized thereafter, while lymphocyte levels showed no significant long-term changes. Monocytes significantly decreased at two weeks but normalized by weeks 9-13. Scanning electron microscopy (SEM) revealed skin changes, including collagen bundle alterations and surface perforations. By week 10, the skin showed well-defined collagen structures and dense papillae, while earlier weeks exhibited more pronounced damage. These findings highlight HA fillers’ potential short-term physiological and histological impacts, which diminished over time.

Highlights:

 

  1. Hyaluronic acid fillers vary in sources, properties, and clinical effectiveness.
  2. Blood parameters altered early; histological changes observed, diminishing over time.
  3. Fillers cause temporary physiological and histological issues, improving with duration.

 

Keywords: Hyaluronic acid, Histological study, Physiological study, Laboratory rats

References

  1. . A. Mero and M. Campisi, “Hyaluronic acid bioconjugates for the delivery of bioactive molecules,” Polymers (Basel)., vol. 6, no. 1, pp. 346–369, 2014, doi: 10.3390/polym6020346.
  2. . M. S. Choi et al., “Comparative analyses of inflammatory response and tissue integration of 14 hyaluronic acid-based fillers in mini pigs,” Clin. Cosmet. Investig. Dermatol., vol. 14, no. June, pp. 765–775, 2021, doi: 10.2147/CCID.S315076.
  3. . I. S. Kim, J. H., Ahn, D. K., Jeong, H. S., & Suh, “Treatment Algorithm of Complications after Filler Injection : Based on Wound Healing Process,” J. Korean Med. Sci., vol. 29, no. (Suppl 3), pp. 176–182, 2014.
  4. . D. H. Jones et al., “Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations from the American Society for Dermatologic Surgery Multidisciplinary Task Force,” Dermatologic Surg., vol. 47, no. 2, pp. 214–226, 2021, doi: 10.1097/DSS.0000000000002921.
  5. . D. Funt and T. Pavicic, “Dermal fillers in aesthetics: An overview of adverse events and treatment approaches,” Clin. Cosmet. Investig. Dermatol., vol. 6, pp. 295–316, 2013, doi: 10.2147/CCID.S50546.
  6. . A. J. Vartanian, A. S. Frankel, and M. G. Rubin, “Injected hyaluronidase reduces Restylane-mediated cutaneous augmentation,” Arch. Facial Plast. Surg., vol. 7, no. 4, pp. 231–237, 2005, doi: 10.1001/archfaci.7.4.231.
  7. . H. J. Joo, Y. J. Woo, J. E. Kim, B. J. Kim, and H. Kang, “A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Lidocaine-Containing Monophasic Hyaluronic Acid Filler for Nasolabial Folds,” Plast. Reconstr. Surg., vol. 137, no. 3, pp. 799–808, 2016, doi: 10.1097/01.prs.0000479965.14775.f0.
  8. . W. C. Kwak, S. S., Yoon, K. H., Kwon, J. H., Kang, W. H., Rhee, C. H., Yang, G. H., ... & Son, “Comparative analysis of hyaluronidase-mediated degradation among seven hyaluronic acid fillers in hairless mice,” Clin. Cosmet. Investig. Dermatol., vol. 14, pp. 241–248, 2021, doi: 10.2147/CCID.S300960.
  9. . S. H. Hwang, D. H. Kim, B. M. Nam, J. Y. Mun, Y. H. Seong, and S. W. Kim, “Efficacy and Safety of Lyophilized Articular Cartilage Matrix as an Injectable Facial Filler,” Aesthetic Plast. Surg., vol. 45, no. 3, pp. 1266–1272, 2021, doi: 10.1007/s00266-020-02017-1.
  10. . World Health Organization, “World Development Report 1993: Investing in Health,” World Bank, vol. 1, 1993.
  11. . S. M. Dacie, J. V. and Lewis, “Practical haematology,” Edinburgh . Curchill. Livingstone, vol. 6th ede, pp. 40–55, 1984.
  12. . Y. Liu and D. Fan, “Novel hyaluronic acid-tyrosine/collagen-based injectable hydrogels as soft filler for tissue engineering,” Int. J. Biol. Macromol., vol. 141, pp. 700–712, 2019, doi: 10.1016/j.ijbiomac.2019.08.233.
  13. . L. M. Sullivan, “Essentials of biostatistics in public health,” Jones Bartlett Learn., 2017.
  14. . S. Homann et al., “Hyaluronan synthase 3 promotes plaque inflammation and atheroprogression,” Matrix Biol., vol. 66, pp. 67–80, 2018, doi: 10.1016/j.matbio.2017.09.005.
  15. . V. V. P. Laznicek M, Laznickova A, Cozikova D, “Preclinical pharmacokinetics of radiolabelled hyaluronan.,” Pharmacol Rep, vol. 64, no. 2, pp. 428–437, 2012.
  16. . X. Jia et al., “Anti-Inflammatory Effects of the 35kDa Hyaluronic Acid Fragment (B-HA/HA35),” J. Inflamm. Res., vol. 16, no. January, pp. 209–224, 2023, doi: 10.2147/JIR.S393495.
  17. . R. C. Gupta, R. Lall, A. Srivastava, and A. Sinha, “Hyaluronic acid: Molecular mechanisms and therapeutic trajectory,” Front. Vet. Sci., vol. 6, no. JUN, 2019, doi: 10.3389/fvets.2019.00192.
  18. . S. Vasvani, P. Kulkarni, and D. Rawtani, “Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies,” Int. J. Biol. Macromol., vol. 151, pp. 1012–1029, 2020, doi: 10.1016/j.ijbiomac.2019.11.066.
  19. . A. Fallacara, E. Baldini, S. Manfredini, and S. Vertuani, “Hyaluronic acid in the third millennium,” Polymers (Basel)., vol. 10, no. 7, 2018, doi: 10.3390/polym10070701.
  20. . M. S. Karbownik and J. Z. Nowak, “Hyaluronan: Towards novel anti-cancer therapeutics,” Pharmacol. Reports, vol. 65, no. 5, pp. 1056–1074, 2013, doi: 10.1016/S1734-1140(13)71465-8.
  21. . J. Ma, J. Zhang, X. J. Ma, Y. Lu, D. Tang, and Q. Zhang, “Evaluation of biocompatibility and biodegradability of a new auto-derived injectable soft tissue filler: A preliminary report,” Eur. J. Plast. Surg., vol. 34, no. 6, pp. 479–486, 2011, doi: 10.1007/s00238-011-0565-2.
  22. . F. Wang et al., “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin,” Arch. Dermatol., vol. 143, no. 2, pp. 155–163, 2007, doi: 10.1001/archderm.143.2.155.
  23. . S. J. Frost and P. H. Weigel, “Binding of hyaluronic acid to mammalian fibrinogens,” BBA - Gen. Subj., vol. 1034, no. 1, pp. 39–45, 1990, doi: 10.1016/0304-4165(90)90150-U.
  24. . L. Hong et al., “Hyaluronic acid (HA)-based hydrogels for full-thickness wound repairing and skin regeneration,” J. Mater. Sci. Mater. Med., vol. 29, no. 9, 2018, doi: 10.1007/s10856-018-6158-x.
  25. . A. Sionkowska, B. Kaczmarek, M. Michalska, and K. Lewandowska, “Conference paper Preparation and characterization of collagen / chitosan / hyaluronic acid thin films for application in hair care cosmetics,” pp. 1–11, 2017.
  26. . Z. Su et al., “Enhancement of skin wound healing with decellularized scaffolds loaded with hyaluronic acid and epidermal growth factor,” Mater. Sci. Eng. C, vol. 44, pp. 440–448, 2014, doi: 10.1016/j.msec.2014.07.039.
  27. . N. Yoshiba et al., “Immunohistochemical analysis of two stem cell markers of a-smooth muscle actin and STRO-1 during wound healing of human dental pulp,” Histochem. Cell Biol., vol. 138, no. 4, pp. 583–592, 2012, doi: 10.1007/s00418-012-0978-4.
  28. . J. Carneiro, P. M. Döll-Boscardin, B. C. Fiorin, J. M. Nadal, P. V. Farago, and J. P. De Paula, “Development and characterization of hyaluronic acid-lysine nanoparticles with potential as innovative dermal filling,” Brazilian J. Pharm. Sci., vol. 52, no. 4, pp. 645–651, 2016, doi: 10.1590/S1984-82502016000400008.

Downloads

Download data is not yet available.